Madrigal Pharmaceuticals Hits New 52-Week High of $463.48

Madrigal Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 463.48 on October 1, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 10,115 million.
Over the past year, Madrigal Pharmaceuticals has demonstrated impressive growth, with a remarkable 76.22% increase in stock performance, significantly outpacing the S&P 500's 16.09% gain during the same period. The company has reported outstanding results, including a staggering 1353.76% growth in net sales, with the latest quarterly figures showing net sales of USD 212.8 million.

Despite its current loss-making status, indicated by a negative return on equity of -40.50%, Madrigal has shown resilience with consistent returns over the last three years. The stock's performance has been bolstered by high institutional holdings, reflecting confidence in the company's fundamentals. As Madrigal Pharmaceuticals continues to navigate the competitive landscape, its recent achievements highlight its potential within the industry.